Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines

Clinical Interventions in Aging

Volumn 6, Issue 1, 2011, Pages 281-284

  Stengel, Gabriele ^a   Bee, Eva Kristina ^a  

^a Hautarztpraxis Stengel and Bee   (Germany)

Author keywords

Antibody induced treatment failure; Botulinum toxin type A; Neutralizing antibodies

Indexed keywords

BOTULINUM TOXIN A; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CASE REPORT; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG RESISTANCE; DRUG RESPONSE; DRUG TREATMENT FAILURE; ESTHETIC SURGERY; FEMALE; HUMAN; IMMUNOGENICITY; PATIENT SATISFACTION; TREATMENT DURATION; WRINKLE;

EID: 80755126930     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/cia.s18997     Document Type: Article

References (19)

1. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45(9):1743-1746.
2. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19 Suppl 8: S92-S100.
3. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9(2):213-217.
4. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60(7):1186-1188.
5. Muller K, Mix E, Adib Saberi F, Dressler D, Benecke R. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm. 2009;116(5):579-585.
6. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23(10):1353-1360.
7. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing? Clin Neuropharmacol. 2009;32(4):213-218.
8. Borodic G. Immunologic resistance after repeated botulinum toxin type A injections for facial rhytides. Ophthal Plast Reconstr Surg. 2006;22(3):239-240.
9. Lee S-K. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg. 2007;33(1 Spec No.):S105-S110.
10. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol. 1997;147(1):96-102.
11. Lee JC, Yokota K, Arimitsu H, et al. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology. 2005;151(Pt 11):3739-3747.
12. Carruthers A, Carruthers J. Botulinum toxin products overview. Skin Therapy Lett. 2008;13(6):1-4.
13. Flynn TC, Clark RE 2nd. Botulinum toxin type B (Myobloc) versus botulinum toxin type A (Botox) frontalis study: Rate of onset and radius of diffusion. Dermatol Surg. 2003;29(5):519-522.
14. Flynn TC. Botulinum toxin: Examining duration of effect in facial aesthetic applications. Am J Clin Dermatol. 2010;11(3):183-199.
15. Kawashima M, Harii K. An open-label, randomized, 64-week study repeating 10-and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol. 2009;48(7):768-776.
16. Lawrence I, Moy R. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A. Aesthet Surg J. 2009;29(6 Suppl):S66-S71.
17. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, doubleblind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal dose. Dermatol Surg. 2007;33(1 Spec No.):S51-S59.
18. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: A review, Part 1. Am J Health Syst Pharm. 2006;63(2):145-152.
19. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: A review, Part 2. Am J Health Syst Pharm. 2006;63(3):225-232.